Semmelweis Egyetem Pulmonológiai Klinika
About Semmelweis Egyetem Pulmonológiai Klinika
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
10
Actelion
5
Pfizer
4
Bristol-Myers Squibb
2
United Therapeutics
2
Merck KGaA, Darmstadt, Germany
1
Mirati Therapeutics Inc.
1
NovaRx Corporation
1
OSE Immunotherapeutics
1
OSI Pharmaceuticals
1
SigmaDrugs Research Ltd.
1
Clinical Trials at Semmelweis Egyetem Pulmonológiai Klinika
During the past decade, Semmelweis Egyetem Pulmonológiai Klinika conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 14 clinical trials were completed, i.e. on
average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
2006-09-01
2014-06-01
Completed
1,252
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
2008-10-17
2020-12-07
Completed
550
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
2008-07-01
2013-01-01
Completed
532
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2010-01-01
2015-12-01
Completed
1,069
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2009-09-01
2016-01-01
Completed
347
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
2009-12-01
2014-10-01
Completed
1,156
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
2011-06-16
2015-09-14
Completed
878
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
2014-03-11
2019-01-09
Completed
1,225
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Semmelweis Egyetem Pulmonológiai Klinika" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Actelion" with 5 trials
sponsored, "Pfizer" with 4 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "United Therapeutics"
with 2 trials sponsored. Other sponsors include 2 different institutions and
companies that sponsored additional 12 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis Egyetem Pulmonológiai Klinika"
#1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Semmelweis Egyetem Pulmonológiai Klinika
According to Clinical.Site data, the most researched conditions in "Semmelweis Egyetem Pulmonológiai Klinika" are
"Carcinoma, Non-Small-Cell Lung" (4 trials), "Pulmonary Arterial Hypertension" (4 trials), "Non-Small Cell Lung Cancer" (3 trials), "Non-small Cell Lung Cancer" (2 trials) and "Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Semmelweis Egyetem Pulmonológiai Klinika" in a lesser frequency.
Clinical Trials Intervention Types at Semmelweis Egyetem Pulmonológiai Klinika
Most popular intervention types in "Semmelweis Egyetem Pulmonológiai Klinika" are "Drug" (28 trials), "Biological" (4 trials) and "Other" (3 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (9 trials), "Carboplatin" (6 trials), "Docetaxel" (5 trials), "Pemetrexed" (5 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Semmelweis Egyetem Pulmonológiai Klinika
The vast majority of trials in "Semmelweis Egyetem Pulmonológiai Klinika" are
30 trials for "All" genders.
Clinical Trials Status at Semmelweis Egyetem Pulmonológiai Klinika
Currently, there are NaN active trials in "Semmelweis Egyetem Pulmonológiai Klinika".
undefined are not yet recruiting,
3 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 20 completed trials in Semmelweis Egyetem Pulmonológiai Klinika,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Semmelweis Egyetem Pulmonológiai Klinika, 0 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 20 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".